Intravenous Immunoglobulin Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI4037
Intravenous Immunoglobulin Market size is projected to experience significant growth from 2019 to 2025.
Growing burden of immunodeficiency diseases such as AIDS and hypogammaglobulinemia will stimulate global intravenous immunoglobulin (IVIg) business growth in the forthcoming years. According to the statistics of HIV.gov, nearly 36.9 million individuals worldwide suffered from HIV/AIDS in 2017. With growing immunodeficiency diseases, the demand for immunoglobulin replacement therapy will increase, hence boosting the intravenous immunoglobulin business growth in the forthcoming period.
Rising investment in R&D activities for the development of novel drugs coupled with discovery of new indications for existing therapy will positively impact industry growth. Moreover, favorable government initiatives along with rising approvals of intravenous immunoglobulin drugs for several new indications will assist expansion of intravenous immunoglobulin business over the coming period.
However, stringent regulations and high treatment cost will hamper the growth of the IVIg market. High risks of aftereffects associated with IVIg treatment such as headache, dizziness, nausea, vomiting, tachycardia, itching, hypertension, cough and abdominal pains will further restrain growth of the IVIg market over the forthcoming years.
Hypogammaglobulinemia segment will hold a significant share over the forecast years owing to the increase in prevalence of the disorder. According to the Immune Deficiency Foundation, hypogammaglobulinemia is frequently diagnosed primary immunodeficiency disorder in adult affecting 1 in 25,000 adults in the United States. Rising incidence of hypogammaglobulinemia will increase the demand for intravenous immunoglobulin replacement therapy, thereby fueling industry growth.
Hospitals end-use segment will dominate the global intravenous immunoglobulin market during the forecast period. This is attributed to rise in the preference of hospitals over other alternatives. Intravenous administration of immunoglobulins is majorly conducted in hospitals. Moreover, hospitals provide treatment and care to large number of patients and reimbursement policies that increases the adoption rate of hospitals.
U.S. intravenous immunoglobulin market will show significant growth owing to the increasing preference and approvals of immunoglobulin replacement therapies for the treatment of primary immunodeficiency diseases. For instance, in April 2019, ADMA Biologics received FDA approval for novel intravenous immune globulin, Asceniv. Market players in the region are involved in R&D activities for the development of innovative drugs. Furthermore, favorable initiatives and programs including Immune Deficiency Foundation walk for Primary Immunodeficiency (PI) will further pose lucrative growth opportunity in the foreseeable future.
China intravenous immunoglobulin market is expected to grow in foreseeable future due to expanding patient population susceptible to immunodeficiencies. Increasing healthcare expenditure and rise in investments on R&D activities will positively impact industry growth. Several Chinese fractionators including Creat are currently investing into new, large facilities that utilizes current chromatographic processes to produce plasma products of high quality and efficacy. Moreover, rising awareness and emergence of new industrial start-ups will majorly impact China intravenous immunoglobulin industry growth during the forecast period.
Some of the major market players involved in the global intravenous immunoglobulin market are Baxter Healthcare, CSL Behring, Grifols, Octapharma, Talecris, Shire plc among others. Companies are investing in research and development activities and collaborations to expand their market share and product portfolio. The key players are also involved in development of new plasma centers. For instance, in April 2019, Asceniv of ADMA Biologics received FDA approval for treatment of primary humoral immunodeficiency disease.
Intravenous Immunoglobulin Market by Application, 2014-2025 (USD Million)
- Idiopathic thrombocytopenic purpura
- Guillain–Barre syndrome
- Myasthenia gravis
- Kawasaki disease
- Chronic inflammatory demyelinating polyneuropathy
- HIV Infection
- Refractory Dermatomyositis
- Neonatal Infection
- Bone marrow transplant
Intravenous Immunoglobulin Market by End-Use, 2014-2025 (USD Million)
- Home care
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- CSL Behring
- Bio Products Laboratory
- Kedrion S.p.A.
- LFB Biomedicaments
- Shanghai RAAS Blood Products Co.
- Biotest AG
- Takeda Pharmaceutical Company Limited
- China Biologic Products Holdings, Inc
- BioScrip, Inc.
- ADMA Biologics
- Hualan Biological Engineering Inc.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability